Drugmakers and advocacy groups are closely watching the FDA as it reevaluates its stance on rare disease therapies, signaling a potential shift toward a more flexible regulatory approach after prior leadership tightened approval standards.
The FDA has recently approved several novel treatments for rare diseases, including gene therapies and orphan drugs, and has launched a new "plausible mechanism" framework designed to facilitate approval of highly individualized or ultra‑rare disease therapies based on mechanistic evidence rather than large randomized trials.
Recent regulatory reversals—such as the FDA indicating that existing data for Regenxbio’s and uniQure’s gene therapies could support accelerated approval—have raised hopes among rare‑disease sponsors that the agency is becoming more accommodating.
Sources:
Rare Disease Drugmakers Watch FDA for Renewed Focus on ...
Rare Disease Drug Approvals | FDA
US FDA reverses course on Regenxbio's rare-disease gene therapy ...
Through flux and fluidity, FDA keeps coming back to rare disease
FDA proposes new system for approving customized drugs and therapies for rare diseases
FDA Launches Framework for Accelerating Development ...
FDA rolls out new rare-disease drug playbook
FDA Rare Connections - GovDelivery - Granicus
FDA Advances a “Plausible Mechanism” Framework for Rare ...
FDA updates on rare disease treatments and funding deals - LinkedIn
New Drug Therapy Approval 2025
10 recent FDA approvals for rare diseases - pbccompanion.com